{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:24:44Z","timestamp":1761060284508,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10637-017-0440-5","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T02:10:18Z","timestamp":1486087818000},"page":"524-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib"],"prefix":"10.1007","volume":"35","author":[{"given":"Andrea","family":"Necchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pintarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2015-4317","authenticated-orcid":false,"given":"Francesca","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,3]]},"reference":[{"key":"440_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/annonc\/mdv509","volume":"27","author":"D Raggi","year":"2016","unstructured":"Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, Bellmunt J, Necchi A (2016) Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 27:49\u201361","journal-title":"Ann Oncol"},{"key":"440_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920","journal-title":"Lancet"},{"key":"440_CR3","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH (2016) Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34:3119\u20133125","journal-title":"J Clin Oncol"},{"key":"440_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s10637-016-0328-9","volume":"34","author":"A Necchi","year":"2016","unstructured":"Necchi A, Lo Vullo S, Mariani L, Raggi D, Giannatempo P, Calareso G, Togliardi E, Crippa F, Di Genova N, Perrone F, Colecchia M, Paolini B, Pelosi G, Nicolai N, Procopio G, Salvioni R, De Braud FG (2016) An open-label, single-arm, phase 2 study of the aurora kinase a inhibitor alisertib in patients with advanced urothelial cancer. Investig New Drugs 34:236\u2013242","journal-title":"Investig New Drugs"},{"key":"440_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/sj.cr.7290152","volume":"13","author":"YW Ke","year":"2003","unstructured":"Ke YW, Dou Z, Zhang J, Yao XB (2003) Function and regulation of aurora\/Ipl1p kinase family in cell division. Cell Res 13:69\u201381","journal-title":"Cell Res"},{"key":"440_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1083\/jcb.200204155","volume":"158","author":"TA Kufer","year":"2002","unstructured":"Kufer TA, Sillje HH, Korner R, Gruss OJ, Meraldi P, Nigg EA (2002) Human TPX2 is required for targeting aurora-a kinase to the spindle. J Cell Biol 158:617\u2013623","journal-title":"J Cell Biol"},{"key":"440_CR7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.acthis.2010.05.004","volume":"113","author":"Y Lei","year":"2011","unstructured":"Lei Y, Yan S, Ming-De L, Na L, Rui-Fa H (2011) Prognostic significance of aurora-a expression in human bladder cancer. Acta Histochem 113:514\u2013518","journal-title":"Acta Histochem"},{"key":"440_CR8","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/94.17.1320","volume":"94","author":"S Sen","year":"2002","unstructured":"Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B (2002) Amplification\/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320\u20131329","journal-title":"J Natl Cancer Inst"},{"key":"440_CR9","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","volume":"17","author":"MG Manfredi","year":"2011","unstructured":"Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB (2011) Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora a kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17:7614\u20137624","journal-title":"Clin Cancer Res"},{"key":"440_CR10","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1158\/1078-0432.CCR-12-0571","volume":"18","author":"A Cervantes","year":"2012","unstructured":"Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Rosello S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Manos L, Perez-Fidalgo JA, Fingert H, Baselga J, Tabernero J (2012) Phase I pharmacokinetic\/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18:4764\u20134774","journal-title":"Clin Cancer Res"},{"key":"440_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.canlet.2005.11.015","volume":"242","author":"H Ju","year":"2006","unstructured":"Ju H, Cho H, Kim YS, Kim WH, Ihm C, Noh SM, Kim JB, Hahn DS, Choi BY, Kang C (2006) Functional polymorphism 57Val\u00a0>\u00a0Ile of aurora kinase a associated with increased risk of gastric cancer progression. Cancer Lett 242:273\u2013279","journal-title":"Cancer Lett"},{"key":"440_CR12","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1158\/0008-5472.CAN-04-2149","volume":"65","author":"MT Kimura","year":"2005","unstructured":"Kimura MT, Mori T, Conroy J, Nowak NJ, Satomi S, Tamai K, Nagase H (2005) Two functional coding single nucleotide polymorphisms in STK15 (aurora-a) coordinately increase esophageal cancer risk. Cancer Res 65:3548\u20133554","journal-title":"Cancer Res"},{"key":"440_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082790","volume":"8","author":"W Tang","year":"2013","unstructured":"Tang W, Qiu H, Ding H, Sun B, Wang L, Yin J, Gu H (2013) Association between the STK15 F31I polymorphism and cancer susceptibility: a meta-analysis involving 43,626 subjects. PLoS One 8:e82790","journal-title":"PLoS One"},{"key":"440_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090328","volume":"9","author":"W Tang","year":"2014","unstructured":"Tang W, Qiu H, Jiang H, Wang L, Sun B, Gu H (2014) Aurora-a V57I (rs1047972) polymorphism and cancer susceptibility: a meta-analysis involving 27,269 subjects. PLoS One 9:e90328","journal-title":"PLoS One"},{"key":"440_CR15","unstructured":"Clayton D (2011) dgcGenetics: Personal library of functions for genetics. R package version 1 06"},{"key":"440_CR16","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/annonc\/mdw281","volume":"27","author":"MA Dickson","year":"2016","unstructured":"Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS, Schwartz GK (2016) Phase II study of MLN8237 (alisertib) in advanced\/metastatic sarcoma. Ann Oncol 27:1855\u20131860","journal-title":"Ann Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0440-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:06:29Z","timestamp":1678511189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0440-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,3]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0440-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2017,2,3]]},"assertion":[{"value":"14 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was partially supported by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. The company had no role in the design or conduction of the study, in the collection, analysis or interpretation of the data, or in the preparation, review and approval of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in the present study, involving human participants, were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later revisions and amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}